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På många sätt kan principen ingen nämnd och ingen glömd vara den bästa i ett sådant här 
avsnitt. Det går inte att nämna alla som på sitt sätt har bidragit till den här avhandlingen, 
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haft stor betydelse för arbetets framåtskridande vid olika tidpunkter i processen, men som i 
skrivande stund inte kommer upp i mitt huvud. Så du som har bidragit till den här 
avhandlingen men inte blivit nämnd – tack för din insats och din hjälp.  
Det finns dock finns några personer som har haft avgörande betydelse för tillblivelsen och 
slutresultatet av den här avhandlingen, och som jag särskilt vill tacka.  
Maria Eriksson, min huvudhandledare, som varit med från ax till limpa. Tack för att du 
introducerade mig för forskningen och för alla dina insatser genom åren. När du satte en 
vetenskaplig artikel i min hand en av mina första dagar på Fysiologiska kliniken på 
Karolinska Universitetssjukhuset – för att ha som underlag för ett kliniskt utlåtande – då 
förstod jag att jag var på rätt plats och hade träffat rätt person. Tack för resan vi har gjort 
tillsammans.  
Kenneth Caidahl, bihandledare, som har varit till ovärderlig hjälp med sin stora erfarenhet 
och skarpa blick för detaljer i vetenskapliga texter, och som också har en förmåga att samla 
ihop forskningsgruppen för att under trevliga former diskutera och presentera vetenskapliga 
erfarenheter och resultat.  
Anette Rickenlund, bihandledare, vars stora kunskap inom klinisk fysiologi och – inom 
ramen för den här avhandlingen – särskilt arbetsfysiologi – har varit av största vikt för 
avhandlingens framåtskridande och slutförande.  
Britta Hylander, bihandledare, som var med och initierade PROGRESS-projektet, långt före 
jag kom in i bilden, och som bidragit både med kunskap om PROGRESS-projektet och 
expertis inom njurmedicin. Tack också för din uppmuntran i olika skeden av arbetet med 
avhandlingen.  
Lena Persson, min mentor. Tack för all stöd och uppmuntran som du har gett mig under åren. 
Allt ifrån tips på de bästa KI-kurserna till djuplodande diskussioner om vetenskap och allt 
däremellan.  
Eva Wallén-Nielsen, för professionellt och skickligt utförande av ultraljudsundersökningarna 
av deltagarna i PROGRESS-projektet. Din insats har varit ovärderlig.  
  
Eva Linder-Klingsell, som jag aldrig hann träffa, men vars omfattande arbete och 
ultraljudsundersökningar inom PROGRESS-projektet var mitt underlag för fortsatt forskning 
och har varit av avgörande betydelse för projektet. 
Agneta Aspegren-Pagels, som ständigt varit behjälplig och tillgänglig med detaljerad 
information om patienter och försökspersoner inom PROGRESS. Tack för all din hjälp 
genom åren! 
Carin Wallquist, medförfattare och ”med-doktorand”. Det har varit ett stöd att ”kampera 
ihop” med dig inom PROGRESS-projektet. Tack för att du delat med dig av din 
njurmedicinska kunskap (och databas!) och all din uppmuntran. 
Helena Wallin, medförfattare och ”med-doktorand”. Ditt slit med det tredje delarbetet har 
varit imponerande. Dina kunskaper inom arbetsfysiologi och det stora jobb du lagt ned är en 
viktig del av den här avhandlingen.  
Tack till medförfattarna Stefan Jacobson och Eva Jansson, som bidragit med expertis och 
uppmuntran. 
Flemming Larsen, min tidigare chef – tack vare dig började jag jobba på Fysiologiska 
kliniken på Karolinska Universitetssjukhuset och kunde därmed ta första stegen inom 
forskningen. Tack för din uppmuntran, fina personlighet och humor.  
Elisabeth Berg och Eva Hagel, för ovärderlig kompetens och professionell hjälp med 
statistiken i studierna.  
Ann-Britt Wikström på Institutionen för molekylär medicin och kirurgi, för din otroliga 
hjälpsamhet och för att du har svar på alla frågor.  
Carola Steenberg – du får det svåra att verka enkelt. Din vänlighet och effektivitet är ren 
magi.    
Alla medarbetare på Fysiologiska kliniken på Karolinska Universitetssjukhuset i Solna. Tack 
för all er hjälp, vänlighet och uppmuntran. 
Alla tidigare och nuvarande medarbetare och doktorander i forskningsgruppen på 
Fysiologiska kliniken på Karolinska Universitetssjukhuset i Solna – för stöd, hjälp, 
uppmuntran och trevligt umgänge.  
Alla medarbetare på Karolinska Institutet och Karolinska Universitetssjukhuset i Solna och 
Huddinge, som svarat på frågor om stort och smått under alla år.  
 
 
  
Slitvargarna på ”OnLine English”, som med ofattbar snabbhet och noggrannhet lyckas 
detektera och skriva om oändligt många felaktigheter i mina ofullkomliga texter. / The staff at 
”OnLine English”, for excellent linguistic revisions. Any language errors are entirely mine 
due to some late changes.   
Tack till Moderna Museet i Stockholm, för förmedlande av omslagsbilden. 
Min familj och mina brorsbarn. Heidi och Bob – jag älskar er och önskar er all lycka i era 
framtida liv, vilken väg ni än väljer.  
Måns, som har lärt mig att ingenting varar för evigt. Du finns alltid i mitt hjärta.  
Slutligen vill jag tacka de personer vars bidrag är det viktigaste för studierna och slutsatserna 
som förhoppningsvis kan dras från den här avhandlingen. Alla patienter och friska 
försökspersoner som ställt upp i PROGRESS-studien och bidragit till att föra forskningen 
framåt – utan er skulle inga av dessa studier ha kunnat genomföras.  
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SAMMANFATTNING PÅ SVENSKA 
 
Bakgrund:	  	  
Patienter med kronisk njursvikt – “chronic kidney disease” (CKD) – har högre dödlighet och 
incidens av hjärtkärlsjukdom jämfört med njurfriska. Även lindrigt nedsatt njurfunktion är en 
underskattad riskfaktor för kardiovaskulär sjukdom. De bakomliggande orsakerna till de 
ökade kardiovaskulära riskerna hos individer med nedsatt njurfunktion är sannolikt 
multifaktoriell och en kombination av traditionella riskfaktorer (som till exempel ålder, 
hypertoni, rökning och diabetes) och riskfaktorer specifika för njursjukdom – som till 
exempel sekundär hyperparathyreoidism, rubbad calcium-fosfat metabolism och kronisk 
inflammation. Studier har visat att bland annat ökad kärlstyvhet och förekomst av 
vänsterkammarhypertrofi är associerat med sämre prognos och ökad risk för hjärtkärlsjukdom 
hos patienter med nedsatt njurfunktion och dialysberoende patienter. Dock är kunskapen om 
de exakta mekanismerna begränsade, och det finns ett behov av ökad kunskap om 
associationen mellan lindrigt till måttligt nedsatt njurfunktion och kardiovaskulär sjukdom. 
De flesta studier har hittills fokuserat på patienter med uttalad nedsatt njurfunktion och 
dialysberoende patienter. Man har även studerat individer med lindrigt till måttligt nedsatt 
njurfunktion, men i mindre utsträckning.  
Syftet med studierna i denna avhandling var att med icke-invasiva metoder (arbetsprov samt 
ultraljudsundersökning av hjärta och halskärl) detektera tidiga strukturella och funktionella 
hjärtkärlförändringar hos individer med icke-dialysberoende CKD, med särskilt fokus på 
patienter med lindrigt till måttligt nedsatt njurfunktion.  
Studierna som ingår i denna avhandling baseras på ett större forskningsprojekt, PROGRESS 
2002, som är ett samarbete mellan Fysiologkliniken och Njurmedicinska kliniken på 
Karolinska Universitetssjukhuset i Solna. Inom projektet har patienter med lindrig till måttligt 
nedsatt njurfunktion och uttalat nedsatt njurfunktion samt friska försökspersoner följts under 
fem års tid.  
Patienter	  och	  försökspersoner:	  	  
Rekryteringen av ännu inte dialysberoende patienter med nedsatt njurfunktion av olika grad, 
och friska kontrollpersoner började 2002. Svensktalande individer mellan 18–62 år 
inkluderades. Njursjuka patienter med känd kranskärlssjukdom eller stroke exkluderades. 
Patienter rekryterades konsekutivt i samband med besök på njurmedicinska mottagningen, 
och delades upp i två grupper utifrån njurfunktion vid baslinjeundersökningen, mätt som 
glomerulär filtrationshastighet (GFR) med iohexolclearance: patienter med kraftigt nedsatt 
njurfunktion (49 patienter med GFR <20 ml/min/1.73 m2, motsvarande CKD stadium 4–5) 
och lindrigt till måttligt nedsatt njurfunktion (54 patienter med GFR 50-70 ml/min/1.73 m2, 
motsvarande CKD stadium 2–3). Även 54 friska försökspersoner (GFR ≥80 ml/min/1.73 m2) 
som var ålder- och könsmatchade till gruppen med CKD 2–3, rekryterades som 
  
kontrollgrupp. Patienter med CKD 2–3 och kontrollgruppen följdes under 5 år. 
Exklusionskriterier för samtliga deltagare var njurtransplantation, njurdonator eller 
blodsmitta. För friska försökspersoner dessutom känd hjärtsjukdom, diabetes eller pågående 
behandling mot hypertoni, hyperlipidemi eller annan kronisk sjukdom. Patienter med CKD 
2–3 exkluderades från fortsatt uppföljning i samband med terminal behandling som dialys 
eller transplantation.  
Metodik:	  	  
Vid inklusion genomgick samtliga njurpatienter och försökspersoner en klinisk undersökning, 
biokemiska analyser, 24-timmars blodtrycksmätning, ankeltrycksmätning med beräkning av 
ankel-arm-index (AAI), arbetsprov och ultraljudsundersökning av hjärta (ekokardiografi) och 
halskärl (ultraljudsundersökning av karotisartärer - arteria carotis communis [CCA]). Hos 
patienterna med CKD 2–3 och kontrollgruppen upprepades dessa undersökningar år 3 och år 
5. Klinisk undersökning med bland annat blodtrycksmätning utfördes på Njurmedicinska 
kliniken och arbetsprov och ultraljudsundersökningarna utfördes på Fysiologkliniken. 
Jämförelser mellan patienterna med CKD och kontrollgruppen analyserades avseende 
vänsterkammares struktur och funktion, blodtryck vid vila och arbete, samt analyser av 
kärlens struktur och funktion. Graden av hjärtkärlförändringar korrelerades till riskfaktorer 
som ålder, rökning, hypertoni, blodfetter samt markörer av inflammation.  
Studie	  I-­‐IV:	  
Studie I: I den första artikeln analyserade vi data från ekokardiografi-undersökningarna vid 
baslinjen i de tre grupperna. Undersökningarna omfattade bedömning av hjärtats vänster 
kammare, avseende förekomst av eventuell vänsterkammarhypertrofi och bedömning av 
vänsterkammarfunktion, inklusive kvoten E/e´ – ett mått som används för uppskattning av 
fyllnadstryck och därmed relaxationsförmåga (diastolisk funktion) i vänster kammare. 
Resultat: Patienter med CKD hade högre kvot E/e´ jämfört med kontrollpersoner (E/e´: 
kontrollpersoner 5.00 ± 1.23 mot CKD 4–5 6.36 ± 1.71, P < 0.001 och mot CKD 2–3 5.69 ± 
1.47, P = 0.05), indikerande tecken på förändrad diastolisk vänsterkammarfunktion hos 
patienterna med CKD. Prevalensen av vänsterkammarhypertrofi var högre hos patienterna 
med CKD jämfört med kontrollpersonerna (kontrollpersoner 13% mot CKD 4–5 37%, P = 
0.006 och mot CKD 2–3 30%, P = 0.03). 
Konklusion: Tidiga förändringar i hjärtats struktur och funktion kan observeras hos patienter 
med lindrigt till måttligt nedsatt njurfunktion jämfört med friska försökspersoner, indikerande 
att hos CKD patienter kan tecken på hjärtengagemang påvisas i ett tidigt skede, något som 
kan vara en tidig markör för hjärtsjukdom.  
Studie II: I den andra artikeln analyserades baslinjedata från ultraljudsundersökningarna av 
karotisartärerna i de tre grupperna, med bedömning av kärldiameter, väggtjocklek (intima-
media tjocklek) och kärlfunktion, inklusive ”pressure-strain elastic modulus” (Ep), som är ett 
mått på kärlstyvhet. 
  
Resultat: CCA diametern var större hos patienterna med CKD 4–5 jämfört med patienter med 
CKD 2–3 och kontrollpersoner (CKD 4–5, 6.50 ± 0.79 mm mot CKD 2–3, 6.08 ± 0.56 mm, P 
= 0.003; och mot kontrollpersoner 5.97 ± 0.53 mm, P < 0.001). Ingen signifikant skillnad i 
CCA diameter påvisades mellan CKD 2–3 och friska kontrollpersoner. I multivariabel analys 
var systoliskt blodtryck en viktig faktor för skillnaden i CCA diameter mellan CKD 4–5 och 
de andra grupperna, och i den justerade analysen kvarstod skillnaden i CCA diameter mellan 
grupperna endast vid högre åldrar. Det var ingen signifikant skillnad i intima-media tjocklek 
mellan grupperna. Ep var högre hos CKD 4–5 jämfört med kontrollpersonerna (P = 0.006). 
Konklusion: Patienter med lindrigt till måttligt nedsatt njurfunktion uppvisade inga 
signifikanta skillnader avseende kärlförändringar (”arterial remodeling”) eller kärlfunktion 
jämfört med friska försökspersoner. Endast hos patienter med kraftigt nedsatt njurfunktion 
sågs tecken till förändrad kärlstruktur (vid högre åldrar) och funktion, vilket delvis kunde 
förklaras av högre blodtryck hos de sjukaste patienterna.  
Studie III: I den tredje delstudien analyserade vi baslinjedata från arbetsprov i de tre 
grupperna. Fynden från arbetsprov korrelerades till biokemiska markörer avseende hjärt- och 
njurfunktion, samt inflammation. 
Resultat: Patienter med CKD 2–3 hade signifikant lägre arbetsförmåga jämfört med friska 
kontrollpersoner (185 ± 59 watt mot 221 ± 60 watt, P = 0.004), men högre jämfört med 
patienter med CKD 4–5 (150 ± 54 watt). Maximal hjärtfrekvens (HR) var lägre hos patienter 
med CKD 2–3 jämfört med kontrollpersonerna (161 ± 24 slag/min mot 177 ± 11 slag/min, P 
= 0.001), och ytterligare lägre maximal HR sågs hos patienter med CKD 4–5 (144 ± 31 
slag/min). En signifikant skillnad kvarstod även efter korrigering för behandling med 
betablockad.  
Konklusion: Våra resultat med lägre arbetsförmåga och långsammare hjärtfrekvenssvar under 
och efter arbete hos patienter med lindrigt till måttligt nedsatt njurfunktion jämfört med friska 
kontrollpersoner indikerar att lindrigt till måttligt nedsatt njurfunktion är associerat med 
markörer på ökad kardiovaskulär risk.  
Studie IV: I den fjärde delstudien analyserade vi associationen mellan blodtryck, 
biomarkörer och tidiga hjärtkärlförändringar över tid hos en välbehandlad patientgrupp med 
lindrig till måttlig CKD jämfört med friska försökspersoner. I studien undersöktes olika 
blodtrycksparametrar, samt hjärtat och kärlens struktur och funktion vid 
baslinjeundersökningen, samt vid 3- respektive 5-års uppföljning.  
Resultat: Systoliskt blodtryck, mätt som medelvärde vid 24-timmars blodtrycksmätning, 
ökade något över tid hos de friska försökspersonerna, men inte hos CKD patienterna. CCA 
diametern ökade signifikant under uppföljning hos kontrollerna, men inte hos CKD 
patienterna (förändring mellan baslinjeundersökningen och år 5 i kontroller: +0.154 mm 
[95% konfidensintervall: 0.043-0.265], P = 0.001 och hos patienter med CKD: +0.061 mm [-
0.043-0.165], P = 0.274). AAI ökade signifikant över tid hos CKD patienterna men inte hos 
  
försökspersonerna (förändring mellan baslinjeundersökningen och år 5 hos kontroller: -0.001 
[-0.045-0.044], P = 0.998 och hos CKD-patienter: +0.074 [0.031-0.117], P <0.001). Ep ökade 
inte signifikant över tid varken hos njurpatienter eller friska försökspersoner. 
Konklusion: I denna 5-åriga uppföljningsstudie ökade kärldiameter något över tid hos friska 
försökspersoner med inte hos patienter med lindrig till måttlig CKD, troligen på grund av 
välkontrollerat blodtryck hos njurpatienterna. AAI ökade mer hos njurpatienterna än hos 
försökspersonerna, vilket skulle kunna indikera ökande kärlstyvhet hos njurpatienterna; dock 
bekräftades inte detta fynd av mätning av kärlstyvhet i CCA (beräkning av Ep), som inte 
ökade över tid varken hos njurpatienter eller friska försökspersoner. 
Sammanfattning:	  	  
Hos patienter med lindrigt till måttligt nedsatt njurfunktion, kunde förändringar i systolisk 
och diastolisk vänsterkammarfunktion observeras jämfört med friska försökspersoner, och 
patienter med kronisk njursvikt hade högre förekomst av vänsterkammarhypertrofi jämfört 
med försökspersonerna, indikerande att hjärtförändringar börjar tidigt hos patienter med 
kronisk njursvikt. Dessutom observerades en gradvis försämring av arbetsförmåga hos icke-
dialysberoende njurpatienter, vilket i regressionsanalyser huvudsakligen associerades med 
faktorer av betydelse för syreupptagningsförmåga; maximal HR, hemoglobinnivå och 
slagvolym. Det fanns dock inga signifikanta skillnader i kärlstruktur eller kärlfunktion hos 
patienter med lindrig till måttlig kronisk njursvikt jämfört med friska försökspersoner. Endast 
patienter med avancerad grad av kronisk njursvikt visade tecken på förändringar av kärlens 
struktur och funktion, med systoliskt blodtryck och ålder som viktiga bidragande faktorer. I 
linje med detta visade uppföljningsstudien av blodtryck och hjärtkärlförändringar hos 
patienter med lindrig till måttlig kronisk njursvikt jämfört med friska kontroller att bägge 
grupperna var relativt stabila över tiden. Endast små skillnader kunde observeras mellan 
grupperna avseende blodtryck och hjärtkärlförändringar över tid, och förändringar i systoliskt 
blodtryck och kärldiameter var till och med något mer uttalade hos de friska 
försökspersonerna, indikerande att god blodtryckskontroll hos patienter med lindrig till 
måttlig kronisk njursvikt skulle kunna sakta ned utvecklingen av hjärtkärlförändringar. 
 
  
  
ABSTRACT 
Background	  
Cardiac and arterial remodeling and stiffening occur in end-stage renal disease. The presence 
of cardiovascular (CV) alterations in earlier-stage chronic kidney disease (CKD) is less well 
studied. We evaluated CV structure and function in patients with mild-to-moderate CKD 
(stages 2–3) compared with healthy people and patients with advanced CKD (stages 4–5). 
This thesis is based on a prospective study, PROGRESS 2002, which is a collaborative 
project between the Department of Renal Medicine and the Department of Clinical 
Physiology at the Karolinska University Hospital, Solna, Sweden. 
Aims	  
The aim of this thesis was to study early cardiac and vascular alterations in non-dialysis 
CKD, with special interest in patients with mild-to-moderate CKD. Aerobic exercise 
capacity, changes in blood pressure (BP) at rest and during exercise, and arterial and cardiac 
remodeling and function were assessed to improve understanding of the pathophysiology of 
CV involvement in renal disease. 
Methods	  and	  results	  
In Study I, left ventricular (LV) mass index (LVMI) and systolic and diastolic function were 
evaluated using transthoracic echocardiography, including tissue Doppler imaging, in 103 
patients with CKD (stages 2–3 and 4–5) and 53 healthy controls. The peak systolic 
myocardial velocity (sʹ′), early diastolic myocardial velocity (eʹ′), and early transmitral 
diastolic flow velocity (E) were measured, and E/eʹ′ was calculated. 
CKD patients had a higher mean E/eʹ′ and lower longitudinal systolic function, as assessed by 
atrioventricular plane displacement and sʹ′, than the controls. The prevalence of LV 
hypertrophy (LVH) was higher in CKD patients than in controls. 
In Study II, vascular structure and function were studied using carotid ultrasound in 103 non-
dialysis CKD patients (stages 2–3 and 4–5) and 54 healthy controls. Carotid intima–media 
thickness (CIMT) and common carotid artery (CCA) diameter were measured. Strain, 
stiffness, and the pressure–strain elastic modulus (Ep) of the right CCA were calculated. 
  
CCA diameter did not differ significantly between CKD 2–3 patients and controls. CCA 
diameter was larger in CKD 4–5 patients than in CKD 2–3 patients and controls (CKD 4–5, 
6.50 ± 0.79 mm versus CKD 2–3, 6.08 ± 0.56 mm, P = 0.003; and versus controls, 5.97 ± 
0.53 mm, P < 0.001). However, after adjustment, the difference in CCA diameter was 
significant only for older patients and was dependent on systolic blood pressure (SBP). 
CIMT, strain, and stiffness did not differ significantly between groups, but Ep was higher in 
CKD 4–5 patients than in controls (P = 0.006). 
In Study III, aerobic exercise capacity was studied in 99 patients with non-dialysis CKD 
(stages 2–3 and 4–5) and 54 healthy controls. Peak workload, as a measure of aerobic 
exercise capacity, and peak heart rate (peak HR) were measured during a maximal exercise 
test on a cycle ergometer. Cardiac and vascular ultrasound examinations were performed, and 
muscular function, haemoglobin level, and self-reported physical activity were assessed. 
Peak workload, peak HR, and haemoglobin level were significantly lower in CKD 2–3 
patients than in controls and were lower in CKD 4–5 than in CKD 2–3 patients. Multiple 
regression analysis showed that peak workload was strongly associated with systemic oxygen 
delivery factors, as indicated by stroke volume, peak HR, and haemoglobin level; together 
with age, sex, and height2, these factors explained approximately 80% of individual variation 
in workload in CKD patients, with peak HR contributing most to the variation. Self-reported 
physical activity level was also an independent determinant of peak workload.  
In Study IV, 54 patients with CKD stages 2–3 and 54 healthy controls were included and 
followed for 5 years. Renal function, ambulatory BP monitoring, measurement of ankle–
brachial index (ABI), and carotid and cardiac ultrasound examinations were performed at 
baseline and after 3 and 5 years. CIMT, CCA diameter, elastic properties of the CCA 
(measured as Ep), and LVMI were evaluated. 
In the CKD patients, average 24 h SBP and CCA diameter did not increase significantly from 
the baseline and to year 5, but these both increased in the controls over the same time. The 
ABI increased significantly between the baseline and year 5 in the CKD patients but not in 
the controls. LVMI increased significantly between the baseline and year 5 in both groups, 
but the change over time did not differ significantly between patients and controls. Ep did not 
change over time in either group. 
  
In	  summary	  
Alterations in systolic and diastolic myocardial function were seen in patients with mild-to-
moderate CKD compared with controls. The prevalence of LVH was higher in CKD patients 
than in controls, indicating that cardiac involvement starts early in CKD. These studies 
suggest that there is a gradual deterioration of aerobic exercise capacity in people with mild-
to-severe non-dialysis CKD, which is associated mainly with oxygen delivery factors such as 
peak HR, haemoglobin level, and stroke volume. However, there were no significant 
differences in carotid artery structure or function in patients with mild-to-moderate CKD 
compared with healthy subjects. Only patients with advanced CKD and older patients showed 
signs of arterial remodeling, and SBP and age were important contributing factors to this 
remodeling. Consistent with this observation, a follow-up study of BP and CV changes in 
patients with mild-to-moderate CKD compared with healthy controls showed that these 
factors were relatively stable over time in both groups. Only small differences in BP and CV 
changes between groups were observed over time, and the changes in SBP and CCA diameter 
were slightly more pronounced in the controls. These findings suggest that good control of 
BP in patients with mild-to-moderate CKD might slow the progression of CV changes. 
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CHAPTER 1  
Introduction 
 
	  
	  
Epidemiology	  and	  etiology	  of	  chronic	  kidney	  disease	  
	  
Chronic kidney disease (CKD) is common, especially in an ageing population. In a large 
population based study, the prevalence of CKD between 2006 and 2011 was about 6% of the 
adult population in the Stockholm region in Sweden, and the prevalence was higher (28%) 
among the elderly (aged >75 years). These figures are consistent with those from other 
developed countries.1 The etiology of CKD varies, with diabetic nephropathy, 
glomerulonephritis and hypertension/nephrosclerosis as the most common underlying causes. 
Figure 1 shows the etiology of CKD in Sweden according to the Swedish Renal Registry 
(Yearly report 2017).2  
 
 
Figure	  1.	  Etiology	  of	  CKD	  in	  the	  Swedish	  Renal	  Registry	  (2017).	  	  
	  
Adapted	  from	  the	  Swedish	  Renal	  Registry	  (Svenskt	  Njurregister),	  2017.	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Definition	  and	  classification	  of	  chronic	  kidney	  disease	  
	  
According to Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 
CKD is defined as ”abnormalities of kidney structure or function, present for >3 months, 
with implications for health”.3 In 2002, the National kidney foundation and the Kidney 
Disease Outcomes Quality Initiative (NKF/KDOQI) published a classification of CKD, with 
an updated version in 2013 (Table 1).3,4 The classification is based on glomerular filtration 
rate (GFR), and describes 5 stages, where stage 3 is subdivided into 3a and 3b. Without 
evidence of kidney damage, stage 1 and 2 do not fulfill the criteria for CKD.  
Table	  1.	  Stages	  of	  CKD	  related	  to	  GFR.	  
Stage* GFR,	  ml/min/1.73	  m
2
 Kidney	  damage** Dysfunction 
1 ≥90 + Normal 
2 60–89 + Mild 
3a 45–59 + Mild	  to	  moderate 
3b 30–44 + Moderate	  to	  severe 
4 15–29 + Severe 
5*** <15 + Kidney	  failure 
*	  KDOQI	  Clinical	  Practice	  Guidelines,	  Am	  J	  Kidney	  Dis	  2002,	  2013.	  
**	  According	  to	  blood	  or	  urine	  test	  or	  imaging	  studies.	  
***	  ESRD,	  end-­‐stage	  renal	  disease.	  
	  
Cardiovascular	  disease	  in	  chronic	  kidney	  disease	  
Patients with CKD have an increased risk of cardiovascular (CV) disease (CVD) and all-
cause mortality,5-7 and this risk becomes evident as the glomerular filtration rate (GFR) 
decreases below 60 ml/min/1.73 m2.5 However, inconsistent results have been reported for the 
association between mild-to-moderate CKD and CV risk.7-10  
Mechanisms underlying the association between decreased renal function and CVD are still 
incompletely understood. It has been suggested that hypertension contributes to cardiac 
damage in CKD through induction of left ventricular (LV) hypertrophy (LVH),11 and that the 
prevalence of LVH increases with declining renal function.12-15 However, data on the 
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prevalence of LVH in the early stages of kidney disease are conflicting.16,17 CKD patients are 
exposed to coronary ischemia as a result of a reduction in coronary reserve and capillary 
density.18 Large artery stiffness is an independent risk factor for all-cause and CV mortality in 
both the general and renal disease population.19 Figure 2 summarizes different factors and 
pathways causing CV complications. 
	  
Figure	  2.	  Joint	  impact	  of	  CKD	  and	  hypertension	  on	  the	  CV	  system.	  
 
Reprinted	  from	  Kidney	  International.,	  2010;	  vol	  77,	  Middleton	  et	  al.,	  Hypertension,	  chronic	  kidney	  disease,	  and	  the	  
development	  of	  cardiovascular	  risk:	  a	  joint	  primacy,	  Pages	  No.	  753–755,	  Copyright	  2018,	  with	  permission	  from	  Elsevier.	  
 
Most of the prevalence and prognostic studies in CKD have been performed in patients with 
end-stage renal disease (ESRD). The association between mildly reduced GFR and CVD has 
been studied, but much less.8,20 The relationships between biomarkers and the risk profile of 
patients with mild-to-moderate CKD and the prevalence of increased carotid intima–media 
thickness (CIMT), arterial stiffness, and variables of cardiac function have not been well 
characterized. Exercise tolerance and the blood pressure (BP) response to exercise have been 
studied infrequently non-dialysis CKD patients. 
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Studying biomarkers in relation to cardiac and vascular function in patients with mild-to-
moderate CKD may increase understanding of initial pathways of the disease and the 
significance for its progression. Both traditional risk factors, such as age and hypertension 
and non-traditional factors, such as anemia, chronic inflammation, oxidative stress, and 
abnormalities in mineral metabolism, play a role in the pathogenesis of CVD in CKD. 
Despite growing recognition of the frequent presentation of combined cardiac and renal 
dysfunction, the “cardio–renal syndrome”, the extent of CV abnormalities and underlying 
pathophysiology are not completely understood, especially in patients with mild-to-moderate 
renal dysfunction. Inflammation is an acknowledged part of the pathophysiological process of 
atherosclerosis,21,22 and increased levels of various inflammatory markers are characteristic in 
both CVD and CKD.23  
 
Left	  ventricular	  mass	  and	  function	  
The increased CV risk in CKD patients is associated with cardiac remodeling, and the 
development of LVH.12,24-26 In non-dialysis CKD patients, LVH was found to be the 
strongest predictor of progression to ESRD or death.27 In a large cross-sectional study, the 
prevalence of LVH in non-dialysis CKD patients ranged from 32% in patients with estimated 
GFR (eGFR) ≥60 ml/min/1.73 m2 to 75% in patients with an eGFR <30 ml/min/1.73 m2.28  
Reduced kidney function is also a risk factor for the development of heart failure.29,30 Mild 
renal dysfunction has been shown to be a strong predictor of congestive heart failure with 
preserved LV ejection fraction (LVEF).31 Diastolic myocardial function was reported being 
worse in patients with CKD than in hypertensive patients with normal renal function, 
especially in those with more advanced stages of CKD.13 Left atrial size is influenced by 
impaired LV filling and has been shown to be a predictor of mortality in ESRD patients with 
LVH.32 In ESRD, the risk of CV events was found to be highest in patients with both LVH 
and reduced LV function.33 However, results showing an association between a decline in 
renal function and LV function are inconsistent.13,14,28,34-37 
Global systolic LV function is conventionally measured as LVEF, which is calculated from 
simplistic models using diastolic and systolic dimensions or volumes.38 In the last decade, the 
interaction between the complicated structure and orientation of myocardial fibers and 
contractile LV function has been clarified.39 Longitudinal contraction of the left ventricle can 
be measured by atrioventricular (AV) plane displacement with the use of M-mode and/or 
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systolic myocardial velocity using tissue Doppler imaging (TDI). Evaluation of diastolic LV 
function has also been influenced by the development of TDI by adding variables calculated 
from transmitral flow and diastolic myocardial velocities. 
Although changes in LV geometry have been demonstrated in patients with CKD, the 
association between renal function and impaired cardiac function has not been established, 
especially when traditional echocardiographic methods are used.28 TDI can provide a 
quantitative evaluation of myocardial function and has an advantage over conventional 
echocardiography in diagnosing subclinical alterations in systolic and diastolic LV 
function.40,41 In patients with advanced CKD, subclinical diastolic LV dysfunction, as 
assessed by TDI, has been found to be associated with adverse outcome.42,43 TDI has been 
shown to be a more sensitive tool than conventional echocardiography for the detection of 
impaired diastolic function in CKD patients.34,44 Only a few studies have evaluated systolic 
function in CKD when using TDI.35,37,44,45 
 
Exercise	  capacity	  in	  chronic	  kidney	  disease	  
Patients with ESRD have reduced exercise tolerance and suffer from physical inactivity. 
Exercise capacity, measured as peak work capacity or peak oxygen uptake (VO2peak), is 
impaired in ESRD patients.46-51 Exercise capacity, measured as VO2peak, is a strong predictor 
of survival in ESRD.52   
The mechanisms underlying reduced exercise capacity in CKD patients are multifactorial and 
not fully understood. Contributing factors include congestive heart failure,53 physical 
inactivity,54,55 and abnormal neurocirculatory control and hemodynamic responses during 
exercise.56  
Exercise capacity and BP response to exercise in non-dialysis-dependent CKD patients have 
only been little studied. Faria et al. showed that, compared with healthy controls, non-dialysis 
patients with CKD stages 3–5 had lower maximal and submaximal exercise tolerance, 
measured in a cardiopulmonary exercise test (ergometric treadmill, ramp protocol) and 6-
minute walk test, respectively.57 
Heart rate (HR) recovery after exercise has been shown to be a predictor of CV risk.58-60 In a 
cohort of CKD patients with IgA nephropathy, reduced HR recovery was associated with 
decreased eGFR. Patients with eGFR <60 ml/min/1.73 m2 had a reduced HR recovery 
compared with patients and controls with higher eGFR.61 
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It has been reported that aerobic exercise capacity is associated with an inflammatory state in 
CKD patients, independent of the presence of diabetes.62  
CKD and anemia have been shown to be independently associated with reduced physical 
function and exercise capacity in patients with coronary artery disease, and that these effects 
were additive.63  
	  
Carotid	  intima–media	  thickness	  and	  vascular	  function	  
Vascular calcification is common in CKD and can occur in the intima and/or media of the 
arterial wall in various vascular beds, leading to arterial stiffness (arteriosclerosis) and 
calcified occlusive lesions (atherosclerosis).64 In CKD patients and the general population, 
elevated serum phosphate levels have been correlated with increased risk of CV and all-cause 
mortality, and play a role in vascular calcification. Hyperphosphatemia promotes vascular 
calcification, partly by inducing vascular smooth muscle transformation into osteoblastlike 
cells.65  
CIMT as measured by carotid ultrasound, is an accepted marker to predict CVD.66 In the 
general population, increased CIMT predicts adverse CV events.67 CIMT has been shown to 
be an independent predictor of CV mortality in dialysis patients,68 and a predictor of CVD in 
non-dialysis CKD patients.69,70 CIMT has also been demonstrated to be associated with 
inflammation in non-dialysis CKD patients.71 It has been reported that decreased kidney 
function is associated with a faster increase in CIMT.72 In CKD stages 4 and 5, arterial 
stiffness is an independent predictor of CV events.73 
There is need of better understanding of the prevalence of subclinical atherosclerosis in 
earlier stages of CKD. Non-invasive techniques, such as carotid ultrasound, can be used to 
evaluate the atherosclerotic burden in CKD patients without a previous CV event. Arterial 
stiffness assessment using carotid ultrasound examination may help in describing the early 
phases of vascular wall remodeling in subclinical vascular disease.  
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CHAPTER 2  
Aims 
 
The overall aim of this thesis was to compare the pathophysiological changes in the CV 
system between patients with non-dialysis CKD at different stages and healthy controls. Of 
special interest was to identify clinically relevant abnormalities of early cardiac and vascular 
alterations in mild-to-moderate CKD, which may have clinical implications for patient 
management and risk stratification. It was hypothesized that patients with mild-to-moderate 
CKD would show signs of early CV abnormalities, as measured using different non-invasive 
techniques. The specific aims of the studies were: 
Study	  I	  
To investigate whether cardiac structure and function differ between patients with mild-to-
moderate CKD, those with advanced CKD, and healthy controls. 
Study	  II	  
To evaluate vascular structure and function in patients with mild-to-moderate and advanced 
CKD in comparison with healthy controls. 
Study	  III	  
To assess aerobic exercise capacity in patients with mild-to-moderate or advanced CKD, to 
compare this with exercise capacity in healthy controls, and to identify factors associated 
with of exercise capacity in CKD patients. 
Study	  IV	  
To study BP and CV changes over time in patients with mild-to-moderate CKD compared 
with healthy controls. 
  
 
   8 
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CHAPTER 3  
Methods 
 
	  
The	  PROGRESS	  2002	  study	  
This thesis is based on the single-center, prospective observational cohort study PROGRESS 
2002. The study is a collaboration between the Department of Renal Medicine and the 
Department of Clinical Physiology at the Karolinska University Hospital, Solna, Sweden. 
	  
Patients	  and	  control	  subjects	  	  
Enrolment of patients with CKD of different severity levels and healthy controls started in 
2002 and was completed in 2009. Swedish-speaking people aged 18–62 years were included. 
CKD patients were divided into two groups: mild-to-moderate CKD (54 patients with GFR 
50–70 ml/min/1.73 m2, corresponding to CKD stages 2–3) and advanced CKD (49 patients 
with GFR <20 ml/min/1.73 m2, corresponding to CKD stages 4–5). Patients with known 
current malignancy were excluded. A group of 54 healthy controls (54 controls with GFR 
≥80 ml/min/1.73 m2), matched for age, sex and living area to the group with mild-to-
moderate CKD was recruited. Of these, 31 were recruited by excerpt from the Swedish Total 
Population Register. This method of recruiting was later replaced, and 23 healthy controls 
were recruited by advertisement at the Karolinska University Hospital web site. People who 
were interested in participating underwent an interview about their health history and 
medication. Measurement of GFR by iohexol clearance was performed in all CKD patients 
and controls at baseline. The inclusion criteria for the controls were: GFR ≥80 ml/min/1.73 
m2; absence of kidney disease, CVD, and diabetes; and not taking any medication on an 
ongoing basis.  
The exclusion criteria for all participants were kidney transplantation, kidney donation, or the 
presence of blood-transmitted disease. Patients with mild-to-moderate CKD and healthy 
controls were followed for 5 years. Patients in the mild-to-moderate CKD group were 
excluded from the further follow-up if they had undergone terminal treatment such as hemo- 
or peritoneal dialysis, or kidney transplantation. All follow-up visits of the participants were 
completed by the end of 2014. 
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In the studies of this thesis, the number of participants varied slightly at baseline due to the 
specific study design and methodology of each study (Figure 3).   
Figure	  3.	  Number	  of	  CKD	  patients	  and	  controls	  at	  baseline.	  	  
 
	  
Ethical	  considerations	  	  
The study protocol was reviewed and approved by the Local Ethics Committee at Karolinska 
Institutet (Reference number: 02-052) and all participants gave their written informed 
consent.  
The study protocol approved included fasting blood samples for the analysis of biomarkers, 
tests for aerobic work capacity and muscle strength, ambulatory BP monitoring (ABPM), 
cardiac and carotid ultrasound. Ultrasound investigations of the heart and carotid arteries are 
non-invasive investigations that involve no radiation and have no known risks.  
Ethical	  permits	  
1. Dnr 02-052. KI research committee Nord at Karolinska University Hospital processed 
application at the committee meeting 2002-02-04. 
Title: Factors with impact on progression of renal failure. 
APPROVED 2002-05-24  
2. Dnr 02-052. Additional application 2003-03-24.  
Title: Factors with impact on progression of renal failure. 
COMPLETION APPROVED 2003-04-02.  
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Measurement	  and	  estimation	  of	  glomerular	  filtration	  rate	  (Studies	  I-­‐IV)	  
Iohexol clearance was used to measure GFR at the baseline in CKD patients and controls.74 
At the follow-up, eGFR was calculated using the Chronic Kidney Disease–Epidemiology 
Collaboration (CKD–EPI) equation.75 The CKD–EPI equation is based on BSA, serum 
creatinine concentration, age, sex, and ethnicity, and was chosen because it has been shown 
to provide a more precise estimate of filtration capacity in the range observed in people with 
mild CKD. 
	  
Ultrasound	  examinations	  (Study	  I-­‐IV)	  
All echocardiographic and carotid ultrasound examinations were performed by two 
experienced sonographers using an ultrasound machine with a 4-MHz probe equipped with 
TDI capabilities (Sequoia 512, Siemens Medical Solutions, Mountain View, CA) and stored 
digitally on magneto optical discs and on an EchoPAC server (Image Vault 5.0 system, 
General Electric Company, Horten, Norway). 
	  
Transthoracic	  echocardiography	  (Studies	  I,	  III	  and	  IV)	  	  
Two-dimensional (2D), M-mode and Doppler echocardiography were acquired according to 
the guidelines of the American Society of Echocardiography (ASE).38 Standard 
echocardiographic 2D images from the parasternal long-axis view were obtained for the 
measurements of LV dimensions, including LV end-diastolic internal diameter (LVIDd), 
end-diastolic interventricular septal wall thickness (SWTd), end-diastolic LV posterior wall 
thickness (PWTd) and left atrial end-systolic diameter (LADs). LV mass (LVM) and LVEF 
were calculated, preferably from M-mode recordings in the standard parasternal long-axis 
view or, if that was not possible, from 2D images. LVM was calculated using the formula 
initially described by Devereux et al. and recommended by the ASE 38,76:  
LVM = 0.8 × (1.04[(LVIDd + PWTd + SWTd)3 – (LVIDd)3]) + 0.6 g 
LVM index (LVMI) was calculated as LVM/body surface area (BSA). LVH was defined as 
LVMI >95 g/m2 for women and >115 g/m2 for men, according to ASE recommendations.38 
LVEF was calculated using the Teichholz method.77 The AV plane displacement was 
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measured from M-mode recordings at the mitral annulus adjacent to the septal, lateral, 
anterior and inferior LV wall.78 The early transmitral diastolic flow velocity (E), E 
deceleration time, and flow velocity during atrial contraction (A) were recorded using pulsed 
Doppler, and the E/A ratio was calculated. Figure 4 shows examples of the echocardiographic 
measurements.  
Figure	  4.	  Examples	  of	  the	  echocardiographic	  measurements.	  	  
 
Upper	  row:	  2D	  measurements	  of	  LV	  dimension,	  M-­‐mode	  measurements	  for	  assessing	  LVM	  and	  LVEF.	  Lower	  
row:	  M-­‐mode	  measurements	  of	  AV	  plane	  displacement	  in	  the	  lateral	  part	  of	  the	  mitral	  annulus	  (LAT),	  TDI	  
measurements	  in	  the	  septal	  part	  close	  to	  the	  mitral	  annulus	  (SEPT).	  
 
Tissue	  Doppler	  imaging	  
TDI was used to record the early diastolic myocardial velocity (e′), late diastolic myocardial 
velocity (a′), and peak systolic myocardial velocity (s′) at the septal, lateral, inferior, and 
anterior basal regions of the LV wall (at end-expiration). The E-wave velocity and e′ obtained 
at the septal and lateral sites were used to calculate the septal and lateral E/e′ ratios. Both 
values and the mean E/e′ ratio (mean value of the septal and lateral E/e′ ratios) were used as 
estimates of the LV filling pressure. The mean of the s′ velocities of the four sites was 
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calculated and used for assessing LV systolic function. All TDI variables are presented as the 
measurement of one cardiac cycle.  
	  
Carotid	  ultrasound	  (Studies	  II,	  III	  and	  IV)	  
The carotid ultrasound examinations included measurements of CIMT and the diameter of 
the common carotid artery (CCA) and calculations of the elastic properties of the CCA, 
according to a standardized protocol.79  
CCA diameter and CIMT were measured just proximal to the bulb on 2D images in the 
longitudinal plane, captured in the end-diastolic phase, assisted by electrocardiogram (ECG). 
The CCA diameter was measured from the leading edge of the near wall echogenic intima–
media (IM) line to the leading edge of the luminal echo of the far wall. CIMT was measured 
in the far wall of the CCA and was defined as the distance between the leading edge of the 
luminal echo and the leading edge of the media/adventitia echo. CIMT was measured as the 
mean thickness over a length of 1 cm (Figure 5). CCA diameter and CIMT were measured 
separately for the left and right CCA, and the averages were calculated. 
Figure	  5.	  2D	  measurements	  of	  CCA	  diameter	  and	  CIMT.	  
 
An M-mode recording of the right CCA just proximal to the bulb in the longitudinal plane 
was obtained for measurements of the systolic and diastolic CCA diameters used for 
calculations of strain, stiffness, and the pressure–strain elastic modulus (Ep). 
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Figure	  6.	  M-­‐mode	  measurements	  for	  calculations	  of	  the	  elastic	  properties	  of	  the	  CCA.	  
 
CCA diameters were measured from the leading edge of the echogenic near-wall IM echo to 
the leading edge of the far wall (Figure 6). CCA diameters in systole (Dsyst) and diastole 
(Ddiast), the systolic BP (SBP) and the diastolic BP (DBP) (measured in the right arm 
immediately before and after the M-mode scan) were used in the equations below. 
Strain was defined as the amount of deformation relative to the unstressed state 
(dimensionless), according to the equation:  
Strain = (Dsyst – Ddiast)/Ddiast. 
Ep, the pressure–strain elastic modulus, which is one measure of distensibility, was defined 
as the equation described by Peterson et al.,80 as below:  
Ep = K × (SBP – DBP)/strain.  
K = 133.3 and is the factor for converting mmHg to N m–2. 
Wall stiffness (dimensionless) was calculated according to the equation by Kawasaki et al.,81 
where ln(SBP/DBP) is the natural logarithm of the ratio of SBP to DBP:  
Stiffness = ln(SBP/DBP)/strain. 
 
24-­‐hour	  ambulatory	  blood	  pressure	  monitoring	  (Study	  IV)	  
Ambulatory BP monitoring (ABPM) was performed over 24 h from morning to morning with 
a cuff of appropriate size placed on the non-dominant arm. BP was measured three times per 
hour, day and night. The participants were instructed to behave normally but to avoid 
demanding physical activities during the registration period.  
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Ankle–brachial	  index	  (Study	  IV)	  
Ankle–brachial index (ABI) was assessed by duplicate resting measurements of BP in the 
upper arms and ankles. A Doppler stethoscope was used to measure the SBP in either the 
posterior tibial or dorsalis pedis artery. The ABI was calculated as the ratio between the SBP 
in each leg divided by the SBP value of the left and right upper arm, respectively, and the 
lowest of the four ratios was selected. Normal ABI was defined as between 0.90 and 1.40.82	  	  
	  
Aerobic	  exercise	  capacity	  (Study	  III)	  
A symptom-limited exercise test on a bicycle ergometer was performed according to clinical 
patient survey practice. The initial workload and workload increase/minute were 
individualized to achieve symptom limitation within 6–10 min. Participants were encouraged 
to continue cycling until exhaustion. Aerobic exercise capacity was defined as the peak 
workload in W, but because different ramps were used, the achieved value was adjusted to 15 
W increments for men and 10 W increments for women.83 Perceived exertion was reported as 
the highest rating on a predefined scale for leg fatigue, dyspnoea, or general exhaustion as the 
limiting symptom.84 Predicted values for expected exercise capacity were derived from a 
Swedish population study that takes into account age, sex, height, and the workload 
increment/minute.85 Resting HR and BP were measured in the supine position before the 
exercise test. Peak SBP was defined as the last measurement made before the end of exercise. 
A continuous 12-lead ECG was used to register the HR response and ST-T segments. 
Predicted peak HR was calculated as 220 minus age. 
 
Muscular	  function	  (Study	  III)	  
The maximum voluntary isometric contraction was measured using a handheld TakeiTM 
dynamometer to determine handgrip strength. The test was performed with the dominant arm 
and the participant in a standing position.  
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Physical	  activity	  level	  (Study	  III)	  
Self-reported physical activity level was rated by the participants using a four-point scale 
modified from the Saltin–Grimby Physical Activity Level Scale,86 which ranges from regular 
exercise on at least three occasions per week (Level 1) to mostly sedentary activities, with 
light exercise for less than 2 hours per week (Level 4).  
	   	  
Biochemical	  analyses	  	  
Fasting blood samples were collected from a peripheral vein in the morning. Plasma and 
serum samples were centrifuged (20 minutes at 3000 rpm), transferred to aliquots, and stored 
at –70 °C pending analyses. Routine assays were performed at the Karolinska University 
Laboratory at the Karolinska University Hospital, Solna, Sweden, which is certified by the 
Swedish Board for Accreditation and Conformity Assessment (SWEDAC). Lipid profiles 
were assessed by measuring the concentrations of total cholesterol and high-density 
lipoprotein (HDL) cholesterol in plasma using enzymatic methods. The concentration of low-
density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula.87 The 
plasma concentrations of high-sensitivity CRP (hs-CRP), calcium, and phosphate were 
measured using routine protocols. 
	  
Statistical	  methods	  
Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 21.0 or 
23.0 (IBM Corp. Armonk, NY, USA). 
In all studies, the results are presented as number and percentage, mean and standard 
deviation (SD), or median and interquartile range, as applicable. Groups were compared at 
baseline using one-way analysis of variance (ANOVA) or the Kruskal–Wallis test if the 
assumptions of normality and homogeneity were not fulfilled. Group comparisons using one-
way ANOVA were followed by a Tukey post hoc test when appropriate. When the Kruskal–
Wallis test was used, a Bonferroni post hoc test was performed for the adjustment of P values 
between groups, when appropriate. For categorical variables, the chi-square test was used. A 
P value <0.05 for a two-tailed test was considered significant. 
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Potential correlations between variables were analyzed using Pearson’s correlation or 
Spearman’s correlation when the correlation seemed to be nonlinear. 
Further specific statistical methods have been used in Studies II, III, and IV, and are 
described below. 
Study II: For CCA diameter, an initial unadjusted analysis was performed to compare CCA 
diameter between the groups, followed by ANOVA adjusted for the background factors SBP, 
age, sex, height, and smoking. Interaction effects were tested for the product of group and 
age, sex, height, SBP, and smoking. 
Study III: To identify factors associated with aerobic exercise capacity in CKD patients, the 
two CKD groups were merged into one group (CKD 2–5). Peak workload was used as the 
dependent variable in multiple linear regression analyses. Adjustments for age, sex, and 
height squared were performed in all analyses, followed by four different strategies:  
1. The increase in explanatory value (R2) for peak workload in both CKD 2–5 and controls 
was tested for single independent variables. 
2. Multiple independent variables were added into a model with peak workload as the 
dependent variable in the CKD 2–5 group. The independent variables included systemic 
oxygen delivery factors, peripheral factors, and diastolic LV function. 
3. Manual forward regression was used to analyze the stepwise increase in explanatory value 
for peak workload in the CKD 2–5 group by adding the significant independent variables 
from the regression analysis described above (Strategy 2). 
4. Clinical determinants – A regression analysis in the CKD 2–5 group, including variables 
that could easily be measured in a clinical setting, such as self-reported physical activity 
level, handgrip strength, and hemoglobin level was performed. 
Study IV: Groups were compared at baseline using Student’s t test or the Mann–Whitney U 
test if the assumptions of normality and homogeneity were not fulfilled. For categorical 
variables, the chi-square test was used. 
Linear mixed models were used to analyze BP and CV changes over time in patients and 
controls. The initial longitudinal analyses were followed by analyses adjusted for different 
background factors such as age, sex, and smoking. 
To compensate for non-normal distributions, CIMT, LVMI, and hs-CRP were log-
transformed (log) when used in the linear mixed-models analyses. 
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CHAPTER 4  
Results 
 
	  
Baseline	  characteristics	  
The clinical characteristics of the study participants are summarized in Table 2. The mean 
age of the participants was 48 years; 60% were men. There were no significant differences 
between the groups in age, sex, body size, or smoking habits. The CKD groups had similar 
etiology of CKD and prevalence of diabetes mellitus but differed significantly in their use of 
medication.  
 
At follow-up (Figure 7) the patients with CKD stages 2–3 and the healthy controls were 
examined after 3 and 5 years, respectively. Two of the CKD patients died (cancer) before 
the end of the follow-up period, but none of the patients progressed to renal replacement 
therapy within the follow-up period of 5 years. However, due to lost to follow-up, a 
reduced number of participants were seen, especially in the control group.  
	  
	  
Figure	  7.	  Patients	  with	  CKD	  2–3	  and	  controls	  at	  baseline	  and	  follow-­‐up	  (Study	  IV)	  
	  
CKD 2–3 
n = 54 
CKD 2–3 
n = 49 
CKD 2–3 
n=49 
Controls 
n = 54 
Controls 
n = 38 
Controls 
n = 43 
Baseline!
!
Year 3 Year 5 
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Table	  2.	  Baseline	  characteristics	  of	  CKD	  patients	  and	  controls.	  
	  
Controls	  
n	  =	  54	  
CKD	  2–3	  
n	  =	  54	  
CKD	  4–5	  
n	  =	  49	  
P	  for	  
comparison	  
between	  
groups	  
GFR,	  ml/min/1.73	  m2	   99.3	  ±	  12.0	   60.1	  ±	  5.2	   15.3	  ±	  3.9	   <0.001	  (all)	  
Age,	  years	   47.5	  ±	  10.6	   46.8	  ±	  10.8	   49.0	  ±	  11.5	   NS	  
Male,	  n	  (%)	  	   33	  (61.1)	   33	  (61.1)	   29	  (59.2)	   NS	  
Current	  or	  past	  smoker,	  n	  (%)	   20	  (37.7)	   27	  (50.9)	   25	  (51.0)	   NS	  
Height,	  m	   1.76	  ±	  0.09	   1.74	  ±	  0.09	   1.73	  ±	  0.10	   NS	  
BSA,	  m2	   1.92	  ±	  0.19	   1.92	  ±	  0.24	   1.91	  ±	  0.23	   NS	  
SBP,	  mmHg	   117	  ±	  12	   123	  ±	  15	   130	  ±	  20	  
<0.001‡	  
0.067§	  
0.090†	  
DBP,	  mmHg	   73	  ±	  8.9	   77	  ±	  10	   78	  ±	  10	  
0.039‡	  
0.055†	  
0.98§	  
LDL,	  mmol/l	   3.36	  ±	  1.12	   3.15	  ±	  0.93	   2.64	  ±	  0.93	  
0.001‡	  
0.038§	  
0.53†	  
Diabetes,	  n	  (%)	   –	   11	  (20.4)	   7	  (14.3)	   NS	  
Diagnosis	  of	  CKD,	  n	  (%)	  
Familial/hereditary/	  
congenital	  diseases	  
–	   14	  (25.9)	   13	  (26.5)	   NS	  
Primary	  glomerulonephritis	   –	   17	  (31.5)	   12	  (24.5)	   NS	  
Secondary	  glomerular/	  
systemic	  disease	  
–	   9	  (16.7)	   10	  (20.4)	   NS	  
Miscellaneous/unknown	   –	   14	  (25.9)	   14	  (28.6)	   NS	  
Medication,	  n	  (%)	  
Diuretics	   –	   12	  (22.2)	   34	  (69.4)	   <0.001	  
ACE	  inhibitors	   –	   23	  (42.6)	   29	  (59.2)	   NS	  
Angiotensin	  II	  receptor	  blockers	   –	   22	  (40.7)	   23	  (46.9)	   NS	  
Beta-­‐blockers	   –	   11	  (20.4)	   20	  (40.8)	   0.024	  
Calcium	  channel	  blockers	   –	   10	  (18.5)	   28	  (57.1)	   <0.001	  
Statins	   –	   13	  (24.1)	   32	  (65.3)	   <0.001	  
CKD	  =	  chronic	  kidney	  disease;	  n	  =	  number;	  GFR	  =	  glomerular	  filtration	  rate	  (measured	  by	  iohexol	  clearance);	  
BSA	  =	  body	  surface	  area;	  LDL	  =	  low-­‐density	  lipoprotein	  cholesterol;	  ACE	  =	  angiotensin	  converting	  enzyme;	  NS	  =	  
not	  significant.	  Values	  are	  reported	  as	  number	  (percentage)	  or	  mean	  ±	  SD.	  P	  values	  were	  obtained	  using	  one-­‐
way	  ANOVA	  for	  continuous	  values	  or	  the	  chi-­‐square	  test	  for	  categorical	  values.	  P	  values	  for	  the	  comparisons	  
between	  groups	  are	  indicated	  as:	  ‡	  =	  CKD	  4–5	  versus	  controls,	  †	  =	  CKD	  2–3	  versus	  controls,	  §	  =	  CKD	  4–5	  versus	  
CKD	  2–3.	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Results	  of	  the	  ultrasound	  measurements	  at	  baseline	  (Studies	  I	  and	  II)	  	  
The main results from the cardiac and carotid ultrasound examinations in the three groups 
(CKD 4–5, CKD 2–3 and controls) at baseline are summarized in Table 3. 
 
Left	  ventricular	  structure	  and	  function	  (Study	  I)	  
LVIDd did not differ significantly between groups. LVMI differed significantly only between 
the CKD 4–5 group and controls (P = 0.006). However, the prevalence of LVH was 
significantly higher in both the CKD 4–5 (37%) and CKD 2–3 (30%) groups than in the 
controls (13%). 
LV radial systolic function, assessed as LVEF calculated using the Teichholz method, did not 
differ significantly between groups. However, there was a tendency towards lower LVEF in 
CKD patients compared with controls (controls 66.0% ± 8.5% vs. CKD 2–3 62.5% ± 7.6%, P 
= 0.09; and vs. CKD 4–5 62.2% ± 9.6%, P = 0.07). In addition, the CKD groups had 
significantly lower longitudinal systolic contraction, measured as the mean of the four sites of 
AV plane displacement, compared with the controls. The mean of the systolic TDI velocities 
of the four sites was also significantly lower in patients than in controls. 
Traditional variables of diastolic function, such as left atrial diameter, mitral E/A ratio, and 
the mitral E deceleration time did not differ between groups. However, the mean E/eʹ′ ratio 
was significantly higher in CKD patients than in controls, indicating alterations in diastolic 
function in the CKD patients compared with the controls. 
	  
Vascular	  structure	  and	  function	  (Study	  II)	  
CCA diameter and CIMT are presented as the average of the left and right CCA. CCA 
diameter was significantly larger in the CKD 4–5 group than in the CKD 2–3 group and 
controls. CIMT did not differ between groups. In the assessment of the elastic properties of 
the CCA, Ep was significantly higher in CKD 4–5 patients than in controls. 
A significant linear correlation was found between CCA diameter and age in the CKD 4–5 
group (r = 0.44, P = 0.001) but not in the other groups (CKD 2–3 r = 0.18, P = 0.19; controls r 
= 0.19, P = 0.16). In the total cohort, CCA diameter correlated inversely with GFR (r = –0.31, 
P < 0.001) and positively with SBP (r = 0.63, P < 0.001). 
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In the adjusted analysis, ANOVA was used to compare CCA diameter between groups after 
adjustment for the background factors age, sex, height, smoking, and SBP, and the 
interaction between group and background factors was also assessed. In the final model, 
age, sex, SBP, and the interaction between group and age were included. The adjusted R2 
for the model was 0.48. In this final model, CCA diameter was dependent on sex (P < 
0.001) and SBP (P < 0.001), but the effect of the factor “group” (with the three categories: 
controls, CKD 2–3, and CKD 4–5) on CCA diameter was no longer significant (P = 0.19). 
However, there was a significant interaction between group and age (P = 0.03) with a 
significant effect of age on CCA diameter only in the CKD 4–5 group. These findings 
indicate that after the adjustments, the difference in CCA diameter between CKD 4–5 and 
the other groups remained only in older patients. 
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Table	  3.	  Main	  results	  for	  the	  echocardiographic	  and	  carotid	  variables	  at	  baseline.	  
Values	  are	  reported	  as	  number	  (percentage),	  mean	  ±	  SD,	  or	  median	  (interquartile	  range)	  for	  skewed	  variables.	  
Abbreviations:	  CKD	  =	  chronic	  kidney	  disease;	  n	  =	  number;	  LADs,	  left	  atrial	  end-­‐systolic	  diameter;	  LVIDd,	  left	  
ventricular	  end-­‐diastolic	  dimension;	  SWTd,	  wall	  thickness	  of	  interventricular	  septum;	  PWTd,	  posterior	  wall	  
thickness;	  LVMI,	  left	  ventricular	  mass/body	  surface	  area;	  LVH,	  left	  ventricular	  hypertrophy;	  LVEF,	  left	  
ventricular	  ejection	  fraction;	  AV,	  atrioventricular	  plane	  displacement;	  E,	  early	  transmitral	  diastolic	  flow	  velocity;	  
A,	  flow	  velocity	  during	  atrial	  contraction;	  sʹ′,	  peak	  systolic	  myocardial	  velocity;	  mean	  sʹ′,	  mean	  peak	  systolic	  
myocardial	  velocity	  of	  the	  septal,	  lateral,	  inferior,	  and	  anterior	  part	  of	  the	  mitral	  annulus;	  eʹ′,	  early	  diastolic	  
myocardial	  velocity;	  mean	  E/eʹ′,	  mean	  septal	  E/eʹ′	  and	  lateral	  E/eʹ′;	  CCA	  =	  common	  carotid	  artery;	  diam.	  =	  
diameter;	  CIMT	  =	  carotid	  intima–media	  thickness;	  Ep	  =	  carotid	  pressure–strain	  elastic	  modulus;	  NS,	  not	  
significant.	  	  
P	  values	  represent	  post	  hoc	  values	  after	  one-­‐way	  ANOVA,	  the	  Kruskal–Wallis	  test,	  or	  chi-­‐square	  test.	  P	  values	  
for	  comparisons	  between	  groups	  are	  indicated	  as:	  ‡	  =	  CKD	  4–5	  vs.	  controls,	  §	  =	  CKD	  2–3	  vs.	  controls,	  and	  †	  =	  CKD	  
4–5	  vs.	  CKD	  2–3.	  
	  
	  
	   Controls	  
n	  =	  53	  
(echo)	  
n	  =	  54	  (CCA)	  
CKD	  2–3	  
n	  =	  54	  
CKD	  4–5	  
n	  =	  49	  
P	  for	  comparison	  
between	  groups	  
LADs,	  cm	   3.38	  ±	  0.48	   3.58	  ±	  0.59	   3.64	  ±	  0.62	   NS	  
LVIDd,	  cm	   4.71	  ±	  0.49	   4.69	  ±	  0.60	   4.65	  ±	  0.56	   NS	  
SWTd,	  cm	   0.99	  ±	  0.16	   1.09	  ±	  0.20	   1.15	  ±	  0.23	   <0.001‡	  0.02§	  
PWTd,	  cm	   0.99	  ±	  0.14	   1.02	  ±	  0.14	   1.09	  ±	  0.19	   0.002‡	  
LVMI,	  g/m2	   91.2	  ±	  17.6	   99.7	  ±	  29.6	   107.0	  ±	  27.2	   0.006‡	  
LVH	   7	  (13)	   16	  (30)	   18	  (37)	   0.006‡	  0.03§	  
LVEF	  Teichholz,	  %	   66.0	  ±	  8.5	   62.5	  ±	  7.6	   62.2	  ±	  9.6	   0.07‡	  0.09§	  
Mean	  AV,	  cm	   1.50	  ±	  0.17	   1.39	  ±	  0.20	   1.40	  ±	  0.21	   0.04‡	  0.01§	  
Mean	  sʹ′,	  cm/s	   11.5	  ±	  1.9	   10.4	  ±	  2.1	   10.4	  ±	  2.1	   0.03‡	  0.02§	  
E/A	  	   1.43	  ±	  0.39	   1.33	  ±	  0.35	   1.24	  ±	  0.49	   NS	  
E	  deceleration	  time	   206	  ±	  47	   203	  ±	  40	   213	  ±	  48	   NS	  
Mean	  E/eʹ′	  	   5.00	  ±	  1.23	   5.69	  ±	  1.47	   6.36	  ±	  1.71	   <0.001‡	  0.05§	  
CCA	  diam.	  average,	  mm	   5.97	  ±	  0.53	   6.08	  ±	  0.56	   6.50	  ±	  0.79	   <	  0.001‡	  0.003†	  0.61§	  
CIMT	  average,	  mm	   0.65	  ±	  0.13	   0.64	  ±	  0.10	   0.63	  ±	  0.11	   NS	  
Ep	  CCA	  right,	  	  
(N	  m–2)	  ×	  104	  
6.10	  	  
(4.77–6.93)	  
6.48	  	  
(5.43–8.10)	  
7.35	  	  
(5.15–9.85)	   0.006
‡	  0.20§	  0.62†	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Exercise	  capacity	  (Study	  III)	  
	  
Exercise	  capacity	  and	  HR	  response	  
In the study population, there was an inverse relationship between CKD stage and achieved 
peak workload as well as peak HR. Peak workload and peak HR were significantly lower in 
CKD 2–3 patients than in controls, and these values were reduced further in CKD 4–5 
patients. The subgroup analysis comparing the CKD patients not taking beta-blockers with 
controls showed similar patterns. During the exercise test, all participants exercised until near 
exhaustion, and perceived exertion did not differ between groups (P = 0.5). 
	  
Determinants	  of	  aerobic	  exercise	  capacity	  in	  CKD	  
Tested as single determinants, systemic oxygen delivery factors (stroke volume (SV), peak 
HR and haemoglobin level), CV factors (including E/eʹ′, LVEF and Ep), handgrip strength, 
and physical activity level were all associated with peak workload in CKD 2–5 patients after 
adjusting for age, sex, and height squared. Among these, peak HR increased R2 the most in 
the CKD patients. Among the systemic oxygen delivery factors, only SV (but not peak HR or 
hemoglobin level) was associated with peak workload after adjusting for age, sex and height 
squared. Handgrip strength and physical activity level were also associated with peak 
workload in the controls. 
Tested as multiple determinants, systemic oxygen delivery factors (SV, peak HR and 
haemoglobin level) contributed significantly to explaining the individual variation in peak 
workload in CKD 2–5 patients after adjusting for age, sex, and height, but handgrip strength, 
Ep and the LV diastolic function variable E/eʹ′ did not.  
The variables SV, peak HR and hemoglobin level were added one by one to a model 
including age, sex, and height squared. Peak HR resulted in the largest increase in R2, from 
0.60 to 0.79. Age did not remain a significant explanatory factor for peak workload when 
peak HR was included in the models. Adding physical activity level in the last step slightly 
increased the R2. 
To control for the use of beta-blockers, a separate multiple regression analysis with age, sex, 
height squared, SV, peak HR, and hemoglobin level was performed in patients not taking 
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beta-blockers (n = 65). In this sub-group analysis, peak HR, SV, and haemoglobin level 
remained as significant explanatory variables for the variation in peak workload. 
The regression model including age, sex, height squared, handgrip strength, hemoglobin level 
and physical activity level produced an R2 value of 0.72. In this model, age, handgrip 
strength, physical activity level and hemoglobin level all significantly contributed to explain 
the variation in peak workload.  
 
Changes	  in	  cardiovascular	  parameters	  at	  the	  follow-­‐up	  (Study	  IV)	  
	  
GFR	  and	  hs-­‐CRP	  concentration	  	  
At baseline, GFR measured by iohexol clearance (ml/min/1.73 m2) was 60.1 ± 5.2 in patients 
with CKD 2–3 and 99.3 ± 12.0 in controls (P < 0.001). At baseline and follow-up, eGFR was 
calculated using the CKD–EPI equation in CKD patients and controls, and the changes over 
time were analyzed using linear mixed models. Both patients and controls exhibited a 
significant decrease in renal function between the baseline and year 5, but the magnitude of 
change over time did not differ significantly between groups (P = 0.159). The hs-CRP 
concentration was higher in CKD patients than in the controls at each time point, but did not 
change significantly over time in either group. 
 
BP	  and	  ultrasound	  measurements	  
As measured by ABPM, the average daytime SBP increased slightly but significantly in the 
controls between the baseline and year 5 but did not change significantly during the same 
period in CKD 2–3 patients. The change over time differed significantly between the groups 
(daytime SBP, P = 0.001). After adjustment for the covariates age-at-inclusion, sex, height, 
and smoking, the increase in daytime SBP in the controls over time remained significant (P = 
0.006), and the difference in the change over time between the groups remained significant (P 
= 0.003). 
ABI increased significantly over time in CKD patients but not in controls; the change 
between the baseline and year 5 was –0.001 [95% confidence interval (CI) –0.045 to 0.044, P 
= 0.998] in controls and +0.074 (0.031 to 0.117, P < 0.001) in CKD patients. 
The CCA diameter increased significantly during follow-up in the controls, but not in the 
CKD patients; the change between the baseline and year 5 was +0.154 mm (95% CI 0.043 to 
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0.265, P = 0.001) in controls and +0.061 mm (–0.043 to 0.165, P = 0.274) in CKD patients. 
After adjustments for age-at-inclusion, sex, height, smoking, and SBP, the increase in CCA 
diameter over time remained significant in controls (P = 0.003). Sex and SBP were the two 
covariates that had a significant effect on CCA diameter (P = 0.005 and 0.001, respectively). 
CIMT increased significantly between the baseline and year 5 in controls but not in CKD 
patients, but the difference in the change between the baseline and year 5 was not significant 
between controls and patients. Vascular function measured as Ep did not change during 
follow-up in patients or controls. LVMI increased significantly between the baseline and year 
5 in both groups. However, there were no significant differences between the groups at any 
time point, and no significant difference between the groups in the change over time.  
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CHAPTER 5  
Discussion 
 
The aim of this thesis was to identify the clinically relevant markers of early cardiac and 
vascular alterations in non-dialysis CKD patients, with special interest in mild-to-moderate 
CKD, to improve understanding of the pathophysiology of early CV involvement in renal 
disease. We hypothesized that even mild-to-moderate CKD patients would show signs of 
early CV abnormalities compared with healthy subjects as shown by different non-invasive 
techniques. 
At baseline, cardiac structure and function differed between patients with mild-to-moderate 
CKD and healthy controls, and the CKD patients had a diminished aerobic exercise capacity. 
By contrast, vascular structure and function did not differ significantly between patients with 
mild-to-moderate CKD and healthy controls. These findings suggest that alterations affecting 
cardiac structure and function, and consequently aerobic exercise capacity, occur earlier than 
vascular changes in CKD. Only patients with advanced CKD showed signs of altered 
vascular structure and function at baseline. 
At the 5-year follow-up, patients with mild-to-moderate CKD showed modest signs of 
progression of CV alterations compared with healthy controls. Renal function decreased over 
the 5 years in both CKD patients and healthy controls, but the change over time did not differ 
significantly between the groups.  
 
Cardiac	  structure	  and	  function	  in	  chronic	  kidney	  disease	  (Studies	  I	  and	  IV)	  
At baseline, the prevalence of LVH was higher in patients with mild-to-moderate or advanced 
CKD than in controls. Using TDI, we found significant alterations in diastolic and 
longitudinal systolic LV function in both groups of CKD patients compared with controls. At 
follow-up, LVMI increased significantly in both mild-to-moderate CKD patients and 
controls, but the change did not differ significantly between these two groups. 
LV	  remodeling	  in	  CKD	  
We found an increased prevalence of LVH in patients with CKD stages 2–3 (30%) and stages 
4–5 (37%) compared with controls (13%); these prevalence rates were similar to those 
described by others.12,13 However, a higher prevalence of LVH in CKD patients has been 
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reported—up to 78% of patients with CKD stages 3–5 and up to 51% of patients with CKD 
stages 1–2.17 The reasons for these diverging results may include different treatment 
strategies in the different patient populations and the use of a different methodology for 
calculating LVM.88  
In non-dialysis CKD patients, it has been reported that LVMI increases with declining renal 
function, and that SBP correlates with LVMI.13,15,89 The prevalence of LVH was found to be 
higher in non-dialysis CKD patients with hypertension than in hypertensive patients without 
CKD.13 Progression of LVM was observed in a longitudinal study of patients with stage 3 
CKD followed for 12 months, despite stable BP and kidney function.90 In Study IV of this 
thesis, in which patients with CKD stages 2–3 were followed over 5 years, LVMI increased 
in patients despite the lack of a significant increase in BP. However, the magnitude of the 
increase in LVMI did not differ between CKD patients and controls in our study. 
 
LV	  systolic	  function	  in	  CKD	  
The association between kidney function and impaired global systolic cardiac function has 
not been clearly established, especially when traditional echocardiographic methods for the 
calculation of LVEF have been used.28 Others have shown that LV myocardial contraction 
and relaxation seem to be impaired first in the longitudinal direction in subclinical patients 
with CV risk factors, who may be comparable to the patients studied in this thesis. Despite 
the impairment of the longitudinal fiber function, the LV pump function (global LVEF) and 
LV filling may be compensated by preserved circumferential shortening at ventricular systole 
and three-directional lengthening at atrial systole, respectively.91 In this thesis (study I), LV 
radial systolic contraction, assessed as LVEF calculated by the Teichholz method, did not 
differ significantly between CKD patients and controls. By contrast, both CKD patient groups 
showed signs of impaired longitudinal systolic contraction with significantly lower systolic 
myocardial velocity (sʹ′) and lower AV plane displacement than controls. These results are 
consistent with those of recent studies using a newly developed ultrasound-based strain-
imaging technique in terms of the impairment of longitudinal systolic function in CKD 
patients.35,37  
 
LV	  diastolic	  function	  in	  CKD	  
Also with regard to diastolic function in CKD, varying results have been reported. A study of 
the association between kidney function and LV diastolic function using traditional methods 
found no graded association.28 The results in this thesis (study I) are consistent with this 
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earlier study because we did not find any significant differences in the traditional 
characteristics of transmitral inflow pattern or left atrial size between CKD patients and 
healthy controls. However, in our study, TDI yielded a significantly higher mitral mean E/eʹ′ 
ratio in both groups of patients (mild-to-moderate and advanced CKD) than in controls. This 
finding indicates altered diastolic function, although most of the CKD patients in the cohort 
had preserved LVEF. These findings are consistent with previous studies showing that TDI is 
a more sensitive tool than conventional echocardiography for the detection of impaired 
diastolic function in CKD patients.34,44  
 
Vascular	  structure	  and	  function	  in	  chronic	  kidney	  disease	  (Studies	  II	  and	  IV)	  
At baseline, CCA diameter did not differ significantly between patients with mild-to-
moderate CKD and well-controlled BP and healthy controls. Only patients with advanced 
CKD had a significantly larger CCA diameter compared with the other groups, which 
suggests that vascular remodeling occurs in advanced CKD. However, in the adjusted 
analysis with CCA diameter as a dependent variable, the difference between patients with 
advanced CKD and the other groups remained valid only for older patients. The difference in 
CCA diameter between the advanced CKD group and the other groups could partly be 
explained by a difference in SBP. CIMT measurement was of limited value as a discriminator 
between the three groups. Analysis of the elastic properties of the CCA at baseline showed no 
significant differences between patients with mild-to-moderate CKD and controls, although 
Ep differed significantly between patients with advanced CKD and controls. 
At the follow-up, the CCA diameter increased significantly over time only in the controls but 
not in the patients with mild-to-moderate CKD. By contrast, ABI increased in CKD patients 
but not in controls, but Ep did not change significantly over time in patients or controls. 
 
Vascular	  remodeling	  in	  CKD	  
In a study of the associations between different vascular biomarkers and prevalent CV events 
in a population at high CV risk, after adjusting for Framingham risk score, CCA diameter 
was the only vascular marker associated with CV events.92 Outward hypertrophic remodeling 
of large arteries has been described in hypertensive people.93 However, Briet and co-workers 
described a phenomenon of maladaptive vascular remodeling in CKD patients that was 
characterized by an increased arterial diameter that was not completely compensated for by 
increased wall thickness.94-96 In their study, they demonstrated a larger CCA diameter but no 
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significant difference in CIMT between patients with mild-to-moderate CKD and 
normotensive or hypertensive people without CKD.94 In study II, we found a similar pattern 
of no difference in CIMT between CKD patients and controls but a larger CCA diameter in 
patients with advanced CKD than in controls. The use of statins in CKD patients, which 
lowers cholesterol concentration, may explain the similar CIMT in CKD patients and 
controls. In our study and the study of Briet and co-workers, CKD patients had lower 
cholesterol concentrations than controls, probably because of statin use. 
There are also some differences between the results in our study and those reported by Briet 
and co-workers.94 In our study, only patients with advanced CKD had a larger CCA diameter 
than controls. However, mean GFR was higher in patients with mild-to-moderate CKD in our 
study (60 ± 5 ml/min/1.73 m2) than in CKD patients in the study by Briet et al. (36 ± 16 
ml/min/1.73 m2). Furthermore, the cohort in our study included a younger CKD population 
(mean age 48 ± 11 years) than in the study by Briet et al. (mean age of CKD patients 58 ± 15 
years). In the adjusted analysis in our study, the difference in CCA diameter between 
advanced CKD patients and the other groups was valid only for older patients. Therefore, 
both the degree of renal dysfunction and patient age should be considered when comparing 
results on arterial remodeling in CKD from different studies. 
A follow-up study found an independent relationship between arterial remodeling, CKD 
progression, and incidence of ESRD.95 The authors reported that CIMT decreased 
significantly during follow-up and that this decrease was associated with an increase in 
carotid internal diameter. Brachial BP remained stable over time in their study. In Study IV of 
this thesis, patients with mild-to-moderate CKD were followed for 5 years, but no significant 
increase in CCA diameter was observed in CKD patients. One possible explanation is that BP 
was well controlled, as evidenced by the lack of a significant increase in average 24 h SBP in 
CKD patients. 
The CIMT measured by carotid ultrasound is a predictor of CVD and is used as a non-
invasive surrogate marker for atherosclerosis.66,67 However, the additional predictive value of 
CIMT measurements over the Framingham Risk Score in the general population has been 
questioned recently.97 In study II of this thesis as well as in some other studies,94,95,98 
measurements of arterial enlargement and stiffness seemed to be more sensitive markers of 
early CV abnormalities in CKD patients and may show change before conventional surrogate 
markers such as CIMT.  
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Arterial	  stiffness	  in	  CKD	  
In ESRD patients, carotid arterial stiffness is increased and has been shown to predict all-
cause and CV mortality.99,100 Analyses of Framingham Heart Study cohorts showed that 
arterial stiffness correlated with albuminuria but not with mild-to-moderate CKD.101 The lack 
of a significant association between carotid arterial stiffness and mild-to-moderate CKD in 
Study II of this thesis is consistent with this observation. By contrast, it has been reported that 
even in people with mild renal insufficiency a lower estimated GFR was associated with 
greater arterial stiffness.102 However, that study included an older population (mean age 68 
years) than the population in this thesis (mean age 48 years), which may explain to some 
extent the differences in results between the two studies.  
In a follow-up study of non-dialysis patients with CKD stages 3–5, aortic stiffness did not 
change, but carotid stiffness and Young’s elastic modulus increased significantly over time, 
although BP remained stable.95 In Study IV of this thesis, SBP as measured by ABPM, and 
the pressure–strain elastic modulus as measured by Ep, remained stable over time in patients 
with mild-to-moderate CKD. 
The ABI is used to assess peripheral artery disease. A population-based study reported that 
the association between high ABI and mortality was similar to that between low ABI and 
mortality, which suggests an upper limit of normal ABI of 1.40.82 A pathologically high ABI 
is thought to reflect arterial stiffness and vascular aging. Both pathologically low and high 
ABI has been found to be more common in CKD patients (stage 3 and higher) than in non-
CKD controls, and pathologically high ABI was more prevalent in patients with more 
advanced CKD.103 In Study IV, ABI increased over time only in patients with mild-to-
moderate CKD but not in controls, which may indicate incipient arterial stiffness in CKD 
patients. However, the values were generally below the upper limit of 1.4 also in the CKD 
patients, which makes the conclusions of this observation uncertain. 
 
Aerobic	  exercise	  capacity	  in	  chronic	  kidney	  disease	  (Study	  III)	  
Reduced peak HR is a known feature of non-dialysis CKD.57,104-107 The mechanisms behind 
the decreased peak HR in CKD are unknown and may involve both cardiac autonomic 
insufficiency108 and peripheral factors (e.g., a low muscle mass and/or mitochondrial 
function, which may reduce oxygen demand leading to a reduction in peak HR), which have 
been proposed for heart failure.109 In study III of this thesis, it was shown that aerobic 
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exercise capacity decreased gradually with CKD stage in the CKD patients. After merging 
the CKD patients in the PROGRESS cohort into one group, including CKD stages 2–5, 
regression analyses showed that peak workload in the patients was strongly associated with 
systemic oxygen delivery factors, such as peak HR, SV, and hemoglobin level, and that peak 
HR increased the R2 value most. In the subgroup analysis of CKD patients not taking beta-
blockers, peak HR remained strongly related to peak workload. These findings suggest that 
chronotropic incompetence is an important factor influencing aerobic exercise capacity in 
CKD patients. The regression models used in study III of this thesis were age adjusted, but 
age did not remain significant when peak HR was included. This may indicate that peak HR 
is more strongly related to exercise capacity than is age in non-dialysis CKD patients. The 
decline in aerobic exercise capacity in healthy people relates primarily to the age-related 
decline in peak HR.110 CKD is linked to premature aging processes,111 but whether reduced 
peak HR is a characteristic of accelerated aging or other CKD factors are the major cause of 
chronotropic insufficiency remains to be explained.  
Hemoglobin level reflects arterial oxygen content and the capacity for systemic oxygen 
delivery. The relationship between reduced hemoglobin level and decreased aerobic exercise 
capacity is well known in association with moderately and severe decreased renal 
function.63,107,112,113 In study III, hemoglobin level decreased gradually in parallel with the 
gradual decrease in exercise capacity in CKD 2–3 and CKD 4–5 patients compared with 
controls.  
CV function influenced peak workload in CKD 2–5 patients. This was evidenced by the 
associations of LV systolic and diastolic function (E/eʹ′), and vascular function (Ep) with peak 
workload in CKD 2–5 patients when tested as single determinants, after adjustments for age, 
sex and height squared. In the multivariable analysis of CKD 2–5 patients that included 
systemic oxygen delivery variables, neither E/eʹ′ nor Ep was independently associated with 
peak workload. Previously, E/eʹ′ and measures of vascular stiffness have been found to be 
independent determinants of aerobic exercise capacity in non-dialysis CKD patients.104,105,114 
The discrepancies between different studies may reflect the choice of variables included in 
multivariable analyses. In study III of this thesis, variables directly linked to oxygen delivery, 
such as SV and peak HR, seem to be markedly stronger determinants of aerobic exercise 
capacity than measures of LV diastolic function and vascular stiffness. By contrast, self-
reported physical activity was significantly associated with peak workload, also after 
adjusting for other factors. In a separate analysis, variables that may be easily measured in the 
clinical setting, such as self-reported physical activity level, handgrip strength and 
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hemoglobin level, along with age, sex and height squared, were independent determinants of 
aerobic exercise capacity in the CKD patients. Physical activity level has been suggested to 
reflect peripheral factors, such as local oxygen transport, diffusion, and extraction by 
mitochondria, and possibly maximal SV.115,116  
 
Cardiovascular	  risk	  reduction	  in	  chronic	  kidney	  disease	  	  
It seems that established risk factors in the general population, such as hypertension and 
smoking, also account for much of the increased CV risk in CKD patients, and that non-
optimal management of these factors is common in CKD patients.117 However, CKD specific 
risk factors, such as mineral bone disorders and anemia, are thought to play an important role 
in the development of CVD in CKD patients. Nonetheless, few trials on non-traditional risk 
factors have demonstrated a significant effect on CV events or mortality.117 Lowering BP has 
been demonstrated to be effective in reducing CV events in patients with moderate CKD, 
with no one group of antihypertensive agents offering an advantage over another.118 
However, treatment of hypertension is considered to be one area in which achievement of 
targets is suboptimal in CKD patients.117,118 In the studies of this thesis, the mild-to-moderate 
CKD patients were recruited from a dedicated nephrology clinic and had well-controlled BP 
over time. The CKD patients were monitored more closely than the controls and received 
aggressive treatment of BP, hyperlipidemia, and proteinuria.  
Measurements of arterial stiffness have been suggested to improve risk prediction above that 
of the Framingham Risk Score in the general population119 and might be of value for risk 
stratification of CKD patients at different stages of the disease, although this remains to be 
investigated.  
In the studies of this thesis, differences in cardiac structure and function and in aerobic 
exercise capacity were observed between patients with mild-to-moderate CKD and healthy 
controls. However, vascular structure and function did not differ between these groups at 
baseline. At follow-up, the patients with mild-to-moderate CKD at baseline showed few CV 
changes compared with healthy controls. 
In summary, the findings of this thesis suggest that it may be possible to slow the progress of 
CV changes in mild-to-moderate CKD patients by applying an active approach to controlling 
BP and other risk factors following current guidelines.	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With the growing knowledge of the optimal treatment and monitoring of CKD, further 
prospective studies with larger populations may help improve understanding of the 
development of CVD in CKD patients in the current clinical context. Longitudinal studies of 
the mechanisms affecting systemic oxygen delivery in CKD patients are required for a deeper 
understanding of the multifactorial basis of the reduced aerobic exercise capacity in CKD 
patients. 
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CHAPTER 6 
Limitations 
 
 
The groups included were relatively small at baseline (~50 patients per group) and, especially 
in the control group, the number decreased further at follow-up. However, the use of a group 
of healthy controls makes the statistical analyses more reliable for detecting early CV 
changes in the CKD population. Measurement of GFR by iohexol clearance in both CKD 
patients and controls at baseline provided an optimal base for the classification of CKD 
stages. To overcome the problem with participants lost to follow-up, analyses were 
performed using linear mixed models to compensate for missing values. 
There were relatively few patients with diabetes in this CKD cohort, which may partly 
explain the slow progression of CV changes over time. Another limitation is that the duration 
of comorbid conditions such as diabetes and hypertension could not be determined. 
In terms of methodology, at the time of patient inclusion we had no possibility of using 
speckle tracking analysis in the evaluation of LV deformation or to measure pulse wave 
velocity to evaluate arterial stiffness. Maximal oxygen uptake was not measured in the 
assessment of aerobic exercise capacity. However, because of the approximately linear 
correlation between workload in cycle ergometry and oxygen uptake120, and the high ratings 
of perceived exertion indicating near-maximal effort in the patients and controls, the results 
could be considered valid measurements of aerobic exercise capacity. 
 
  
   36 
  
   37 
CHAPTER 7  
Conclusions 
 
 
 
In this thesis, the research involving non-dialysis CKD patients and healthy controls describes 
the characteristics and extent of early structural and functional CV changes in CKD, with 
special interest in mild-to-moderate CKD and the impact of different stages of CKD on 
aerobic exercise capacity. 
	  
Specific	  conclusions	  for	  studies	  I-­‐IV:	  
	  
I. TDI showed alterations in systolic and diastolic myocardial function in patients with even 
mild-to-moderate CKD compared with healthy controls. The prevalence of LVH increased 
with increasing severity of CKD. These findings indicate that cardiac involvement is already 
present in mild-to-moderate CKD and may be a precursor of premature cardiac morbidity. 
II. Patients with mild-to-moderate CKD showed no significant differences in carotid artery 
structure or function compared with healthy controls. Only patients with advanced CKD 
and older age showed signs of arterial remodeling, as shown by larger CCA diameter 
compared with patients with mild-to-moderate CKD and healthy controls. These findings 
suggest that vascular alterations occur in advanced CKD and that SBP and age are 
important contributing factors. This emphasizes the importance of hypertension control in 
CKD patients. Measurement of CIMT seems to be of limited value for evaluating vascular 
abnormalities in patients with CKD at all stages of the disease. 
III. Aerobic exercise capacity deteriorates gradually with CKD severity in non-dialysis patients. 
The reduced exercise capacity in CKD patients was associated primarily with reduced peak 
HR and hemoglobin level, factors that are important for systemic oxygen delivery. Patients 
who perform more physical activity have better-maintained aerobic capacity, which may be 
clinically important by counteracting the risk of increased CV morbidity in CKD patients.  
IV. Comparing BP and CV changes in mild-to-moderate CKD patients and healthy controls 
over time, both groups were relatively stable over a 5-year period. BP and CV variables 
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changed only slightly over time in both groups, and the changes in SBP and CCA diameter 
were even slightly more pronounced in the control group. The ABI increased more in mild-
to-moderate CKD patients than in controls, which may indicate incipient arterial stiffness in 
the CKD group. However, carotid distensibility (Ep) did not change significantly over time 
in either group. These findings suggest that good control of BP in mild-to-moderate CKD 
patients may have beneficial effects by slowing the progression of CV changes. 
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